Search Results - "Fortmann, Seth D"

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization by Zeng, Mingbing, Shen, Jikui, Liu, Yuanyuan, Lu, Lucy Yang, Ding, Kun, Fortmann, Seth D., Khan, Mahmood, Wang, Jiangxia, Hackett, Sean F., Semenza, Gregg L., Campochiaro, Peter A.

“…Acriflavine, a fluorescent drug previously used for bacterial and trypanosomal infections, reduces hypoxia-inducible factor-1 (HIF-1) and HIF-2 transcriptional…”
Get full text

Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths by Serebruany, Victor L., MD, PhD, Fortmann, Seth D., BS, Cherepanov, Vasily, MD, Litvinov, Oleg, BS, Kim, Moo Hyun, MD, Marciniak, Thomas A., MD

Get full text

Interferon-dependent signaling is critical for viral clearance in airway neutrophils by Margaroli, Camilla, Fram, Timothy, Sharma, Nirmal S, Patel, Siddharth B, Tipper, Jennifer, Robison, Sarah W, Russell, Derek W, Fortmann, Seth D, Banday, Mudassir M, Soto-Vazquez, Yixel, Abdalla, Tarek, Saitornuang, Sawanan, Madison, Matthew C, Leal, Jr, Sixto M, Harrod, Kevin S, Erdmann, Nathaniel B, Gaggar, Amit

“…Neutrophilic inflammation characterizes several respiratory viral infections, including COVID-19-related acute respiratory distress syndrome, although its…”
Get full text

Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization by Lorenc, Valeria E., Lima e Silva, Raquel, Hackett, Sean F., Fortmann, Seth D., Liu, Yuanyuan, Campochiaro, Peter A.

“…In patients with macular edema due to ischemic retinopathy, aqueous levels of hepatocyte growth factor (HGF) correlate with edema severity. We tested whether…”
Get full text

AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration by Liu, Yuanyuan, Fortmann, Seth D., Shen, Jikui, Wielechowski, Erik, Tretiakova, Anna, Yoo, Stephen, Kozarsky, Karen, Wang, Jiangxia, Wilson, James M., Campochiaro, Peter A.

“…Sustained suppression of VEGF is needed in many patients with neovascular age-related macular degeneration (NVAMD), and gene transfer of a VEGF-neutralizing…”
Get full text

Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy by Hammer, Sandra S., Dorweiler, Tim F., McFarland, Delaney, Adu-Agyeiwaah, Yvonne, Mast, Natalia, El-Darzi, Nicole, Fortmann, Seth D., Nooti, Sunil, Agrawal, Devendra K., Pikuleva, Irina A., Abela, George S., Grant, Maria B., Busik, Julia V.

“…Aims/hypothesis Hyper-reflective crystalline deposits found in retinal lesions have been suggested to predict the progression of diabetic retinopathy, but the…”
Get full text

Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells by Qiu, Shaowei, Sheth, Vipul, Yan, Chengcheng, Liu, Juan, Chacko, Balu K, Li, Hui, Crossman, David K, Fortmann, Seth D, Aryal, Sajesan, Rennhack, Ashley, Grant, Maria B, Welner, Robert S, Paterson, Andrew J, Wende, Adam R, Darley-Usmar, Victor M, Lu, Rui, Locasale, Jason W, Bhatia, Ravi

“…Tyrosine kinase inhibitors (TKIs) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a…”
Get full text

Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage by Silva, Raquel Lima E, Kanan, Yogita, Mirando, Adam C, Kim, Jayoung, Shmueli, Ron B, Lorenc, Valeria E, Fortmann, Seth D, Sciamanna, Jason, Pandey, Niranjan B, Green, Jordan J, Popel, Aleksander S, Campochiaro, Peter A

“…Vascular endothelial growth factor (VEGF)-neutralizing proteins provide benefit in several retinal and choroidal vascular diseases, but some patients still…”
Get more information

Reversible retinal vessel closure from VEGF-induced leukocyte plugging by Liu, Yuanyuan, Shen, Jikui, Fortmann, Seth D, Wang, Jiangxia, Vestweber, Dietmar, Campochiaro, Peter A

“…Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only…”
Get full text

Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models by Fortmann, Seth D., Lorenc, Valeria E., Shen, Jikui, Hackett, Sean F., Campochiaro, Peter A.

“…Vitreous or aqueous humour taps are widely used in patients or large animals with retinal diseases to monitor disease biomarkers, search for novel biomarkers,…”
Get full text

Molecular mechanisms of retinal ischemia by Fortmann, Seth D, Grant, Maria B

“…•In addition to oxygen deprivation, HIF-1α stabilization is also highly dependent upon the metabolic status of the cell.•β-oxidation is a prominent feature of…”
Get full text

The FDA report on vorapaxar in the elderly: A convoluted dilemma by Serebruany, Victor L, Fortmann, Seth D

“…Abstract There are consistent data suggesting that elderly patients benefit from less aggressive antiplatelet strategies following acute coronary syndromes…”
Get full text

The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity by Hackett, Sean F, Seidel, Christopher, Abraham, Sheena, Chadha, Rishi, Fortmann, Seth D, Campochiaro, Peter A, Cooke, John P

“…To investigate the role of nicotinic acetylcholine receptors (nAChRs) in retinal vascular development and ischemia-induced retinal neovascularization (NV). The…”
Get full text

Vorapaxar and optimal aspirin dose: The FDA outlook by Serebruany, Victor L, Fortmann, Seth D, Kim, Moo Hyun

“…Abstract Vorapaxar, a novel thrombin PAR-1 inhibitor, approved for post-myocardial infarction, and peripheral artery disease indications has been tested in 2…”
Get full text

Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics" by Serebruany, V L, Fortmann, S D

“…Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and…”
Get more information

Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge by Serebruany, Victor L, Pokov, Alex N, Fortmann, Seth D, DiNicolantonio, James J

“…The recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition…”
Get more information

Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19 by Fortmann, Seth D., Patton, Michael J., Frey, Blake F., Tipper, Jennifer L., Reddy, Sivani B., Vieira, Cristiano P., Hanumanthu, Vidya Sagar, Sterrett, Sarah, Floyd, Jason L., Prasad, Ram, Zucker, Jeremy D., Crouse, Andrew B., Huls, Forest, Chkheidze, Rati, Li, Peng, Erdmann, Nathaniel B., Harrod, Kevin S., Gaggar, Amit, Goepfert, Paul A., Grant, Maria B., Might, Matthew

“…•To our knowledge, we provide the first evidence implicating SARS-CoV-2+ peripheral blood megakaryocytes in severe disease.•Circulating megakaryocytes warrant…”
Get full text

Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model by Li Calzi, Sergio, Shaw, Lynn C, Moldovan, Leni, Shelley, William C, Qi, Xiaoping, Racette, Lyne, Quigley, Judith L, Fortmann, Seth D, Boulton, Michael E, Yoder, Mervin C, Grant, Maria B

“…Retinopathy of prematurity (ROP) is a disorder of the developing retina of preterm infants. ROP can lead to blindness because of abnormal angiogenesis that is…”
Get full text

Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association? by Serebruany, Victor L, Fortmann, Seth D, Hanley, Daniel F, Kim, Moo Hyun

“…Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with…”
Get full text

Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation by Serebruany, Victor L, Fortmann, Seth D, Rao, Sunil V, Tanguay, Jean-Francois, Lordkipanidze, Marie, Hanley, Daniel F, Can, Mehmet, Kim, Moo Hyun, Marciniak, Thomas A

“…Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, has been evaluated in the successful TRA2P trial and the failed TRACER trial. The drug is currently…”
Get more information